KMT2A and leukemia: For example, recent studies have shown that the use of peptidomimetics disrupting the interaction between KMT2A and WDR5 (a member of the above-mentioned core-complex) in murine cell line reduces the expression of target genes responsible for KMT2A-mediated leukemogenesis and inhibits the growth of leukemia cells [67,68].